Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prolyl 3-hydroxylase 3 (P3H3) is an enzyme of the leprecan family, classified among the collagen prolyl 3-hydroxylases. It catalyzes the post-translational hydroxylation of specific proline residues in collagen alpha chains, which is important for the proper biosynthesis, folding, and assembly of collagens, particularly type IV and V collagens[1][4][7]. It functions as part of a protein complex in the endoplasmic reticulum and may act redundantly with other prolyl 3-hydroxylases[4][5]. P3H3 gene expression is detected in various tissues and can be downregulated through epigenetic silencing in cancers such as breast carcinoma, where it may act as a tumor suppressor[1][4]. Disease associations include breast cancer and ocular tuberculosis, but direct drug interactions or pharmacological inhibitors/activators are not currently described[4][5]. The enzyme’s disruption may therefore impact extracellular matrix organization, tumor progression, and tissue integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prolyl 3-hydroxylase 3 (P3H3).